Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.

ABSTRACT:

Importance

Uncertainty remains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC).

Objective

To compare overall survival of PCS vs NACT in a large national population of women with advanced-stage EOC.

Design, setting, and participants

Retrospective cohort study of women with stage IIIC and IV EOC diagnosed between 2003 and 2011 treated at hospitals across the United States reporting to the National Cancer Data Base. We focused on patients 70 years or younger with a Charlson comorbidity index of 0 who were likely candidates for either treatment.

Exposures

Initial treatment approach of PCS vs NACT, examined using an intent-to-treat analysis.

Main outcomes and

SUBMITTER: Rauh-Hain JA 

PROVIDER: S-EPMC5548189 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature